Russo Felicia
SPDC, Triggiano DSM, ASL BA, Bari.
Riv Psichiatr. 2017 May-Jun;52(3):129-134. doi: 10.1708/2722.27766.
Depression is one of the most common diseases worldwide, with more than 350 million people affected. Although many patients initially show a good response to antidepressant therapy, they tend to suffer from residual symptoms that affect their social, cognitive, physical and psychological domains. Residual symptoms severely impact the patient's global functioning and quality of life and increase the risk of recurrence. In the last few years, pharmacological research has focused on drugs able to mitigate the severity of depressive symptoms and to control persistent cognitive and functional disabilities. A novel antidepressant, with a multimodal mechanism of action that combines the classical inhibition of serotonin transporter (SERT) with the modulation of serotonin receptor activity, is vortioxetine. Its efficacy in the treatment of depression and cognitive symptoms has been well established in numerous randomized clinical trials. Three cases of patients with depressive disorders are presented, in which vortioxetine treatment improved depressive symptoms, cognitive symptoms and overall patient functioning. These anecdotal experiences suggest that vortioxetine, in addition to controlling all symptoms of depression, including cognitive symptoms, provides functional benefits in patients with depressive disorders.
抑郁症是全球最常见的疾病之一,超过3.5亿人受其影响。尽管许多患者最初对抗抑郁治疗表现出良好反应,但他们往往会出现残留症状,这些症状会影响他们的社交、认知、身体和心理领域。残留症状严重影响患者的整体功能和生活质量,并增加复发风险。在过去几年中,药理学研究集中在能够减轻抑郁症状严重程度并控制持续性认知和功能障碍的药物上。一种新型抗抑郁药伏硫西汀具有多模式作用机制,它将经典的5-羟色胺转运体(SERT)抑制与5-羟色胺受体活性调节相结合。其在治疗抑郁症和认知症状方面的疗效已在众多随机临床试验中得到充分证实。本文介绍了3例抑郁症患者的病例,其中伏硫西汀治疗改善了抑郁症状、认知症状和患者的整体功能。这些轶事性经验表明,伏硫西汀除了能控制包括认知症状在内的所有抑郁症状外,还能为抑郁症患者带来功能益处。